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Does morphine remain a standard of 
care in acute myocardial infarction?
ABSTRACT
Morphine is routinely used for pain relief in patients with acute myocardial infarction. However, it was doc-
umented that morphine decreases the bioavailability and antiplatelet effect of P2Y12 receptor inhibitors. 
Multiple strategies to overcome this undesirable interaction are currently under investigation; they include 
the following: administration of crushed ticagrelor tablets, co-administration of metoclopramide, bridging 
with intravenous antiplatelet agents, or replacement of morphine with other analgesic. Adequately pow-
ered randomised trials examining the clinical consequences of concomitant use of morphine and P2Y12 
receptor inhibitors are still lacking.
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Introduction
Alleviation of chest pain is of paramount importance 
in the treatment of patients with acute myocardial 
infarction (MI). Titrated intravenous morphine is the 
most widely used method in this clinical setting [1]. 
The choice of such powerful analgesics as opioids is 
motivated by the necessity of providing comfort, but 
also to attenuate sympathetic activation, which leads to 
vasoconstriction and increased afterload of the heart. 
According to the current European Society of Cardiol-
ogy (ESC) guidelines on acute myocardial infarction in 
patients presenting with ST-segment elevation (STEMI), 
titrated intravenous opioids should be considered 
to relieve pain (class of recommendation IIa, level of 
evidence C) [2]. It is noteworthy that, as compared to 
previous guidelines, the class of recommendation for 
morphine use in STEMI has been lowered from I to IIa 
(i.e. from “it is indicated” to “it should be considered”) 
with the same level of evidence C (i.e. consensus of 
opinion of the experts) due to the unfavourable impact 
of morphine on P2Y12 inhibitors bioavailability and 
antiplatelet effect [2–4]. 
Interaction between morphine and 
antiplatelet agents
Dual antiplatelet therapy composed of aspirin and 
a P2Y12 receptor inhibitor is a cornerstone of treatment 
in patients with acute coronary syndromes (ACS) [4, 
5]. In modern ACS therapy the ESC guidelines clearly 
recommend the use of more potent antiplatelet agents 
like ticagrelor and prasugrel over clopidogrel [6]. In 
a double-blind cross-over trial in healthy volunteers, 
morphine had no significant effect on aspirin-induced 
platelet inhibition [7]. The first reports suggesting 
possible drug-drug interaction between morphine and 
clopidogrel come from the CRUSADE registry [8]. In 
this registry the incidence of the composite endpoint 
of death and myocardial infarction was significantly 
higher in patients who received intravenous morphine 
as compared with those who did not. In a randomised, 
placebo-controlled, pharmacokinetic trial in healthy vol-
unteers the administration of morphine was associated 
with delayed and reduced maximal plasma concentra-
tion of ticagrelor [9]. In the first hours of treatment in 
STEMI, as compared with non-ST-segment elevation 
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myocardial infarction (NSTEMI), ticagrelor concentra-
tions as well as its antiplatelet effect was found to be 
reduced in the prospective, observational PINPOINT 
trial [10]. It was further documented that independent 
predictors of high on-treatment platelet reactivity within 
the initial hours of antiplatelet treatment with ticagrelor 
in ACS patients are the presence of STEMI and mor-
phine co-administration [11]. The first randomised study 
demonstrating the unfavourable interaction between 
morphine and ticagrelor in the acute MI setting was 
the double-blind, placebo-controlled, pharmacokinet-
ic-pharmacodynamic IMPRESSION trial [4]. The study 
provided evidence that morphine decreases not only the 
bioavailability, but also the antiplatelet effect of ticagre-
lor in patients with MI. Similar observations of delayed 
onset of action with concomitant use of morphine were 
also reported for prasugrel [12, 13]. 
The mechanism of interaction between 
morphine and P2Y12 receptor inhibitors
Morphine frequently induces nausea and vomiting 
[14]. Moreover, the stimulation of opioid receptors in the 
myenteric plexus and the intestines is responsible for 
reduction of intestinal motility and production of intes-
tinal secretes [15]. Additionally, increased sympathetic 
activation and selective perfusion of vital organs results 
in delayed stomach emptying, slower intestinal transit, 
and deferred drug absorption. Interestingly, impaired 
gastrointestinal absorption is probably also responsible 
for the delayed antiplatelet effect of potent P2Y12 inhib-
itors observed within the first hours of treatment in MI 
patients managed with mild therapeutic hypothermia, 
as well as in critically ill patients [16, 17]. 
Therapeutic strategies to overcome 
the interaction between morphine and 
P2Y12 receptor inhibitors
Several options have been proposed in the literature 
to either avoid or diminish the undesirable interaction 
between morphine and P2Y12 receptor inhibitors. First, 
administration of crushed ticagrelor tablets as com-
pared with the integral ones was associated with 
shorter time to reach maximum plasma concentration 
of ticagrelor and lower platelet reactivity at one hour 
post loading dose in STEMI patients [18]. It is worth 
mentioning that sublingual administration of crushed 
ticagrelor tablets was related to slower absorption and 
higher platelet reactivity within the first hour following 
ticagrelor loading dose, compared with crushed tablets 
administered orally in patients with unstable angina 
[19]. Second, the co-administration of a prokinetic 
agent — metoclopramide — was associated with higher 
ticagrelor concentration and lower platelet reactivity 
within the first hour post ticagrelor loading dose in 
patients with unstable angina [20]. Third, the idea of 
intravenous co-administration of a peripheral opioid an-
tagonist — methylnaltrexone — showed only marginal 
differences in ticagrelor concentration and no effect on 
platelet reactivity [21]. Fourth, the co-administration of 
a glycoprotein IIb/IIIa receptor antagonist — abciximab 
— provided prompt and efficient platelet inhibition in 
prasugrel-treated STEMI patients receiving morphine 
[13]. Fifth, although it has not been examined yet, 
the co-administration of an intravenous direct-acting 
P2Y12 receptor antagonist — cangrelor — might also be 
a possible solution [22]. And, sixth, the last proposed 
strategy to overcome the negative impact of morphine 
may be a replacement of morphine with another pow-
erful, short-acting opioid analgesic like alfentanil [23]. 
Clinical consequences of interaction 
between morphine and P2Y12 receptor 
inhibitors
Morphine co-administration in ticagrelor-treated pa-
tients with ACS is a strong predictor of high on-treatment 
platelet reactivity within the first hours after ticagrelor 
loading dose, when a sufficient antiplatelet effect is 
particularly desired [11]. High on-treatment platelet 
reactivity is a significant and well-documented risk 
factor of atherothrombotic events [24–26]. It has been 
postulated that delayed onset of antiplatelet action 
in MI patients receiving morphine may translate into 
increased risk of adverse cardiovascular events [4, 9, 
27–29]. However, to date, we lack adequately powered 
randomised studies investigating this hypothesis. Ad-
ditionally, morphine use in STEMI patients is not only 
associated with increased platelet reactivity, but also re-
duced spontaneous myocardial reperfusion and larger 
infarct size [30]. In a recently published meta-analysis 
including one randomised trial and 10 observational 
studies, periprocedural intravenous morphine use in 
STEMI patients treated with an oral P2Y12 receptor 
inhibitor (ticagrelor 59.7%, clopidogrel 33.5%, and pra-
sugrel 6.8%) and undergoing PCI was not associated 
with adverse short-term clinical outcomes [31]. Yet, 
the included randomised trial comprised only 35 mor-
phine-treated subjects, and there was only one reported 
adverse event [4]. Further randomised trials exploring 
the effect of morphine use on clinical outcomes in MI 
patients are greatly needed.
48
Medical research journal 2020, vol. 5, no. 1
www.journals.viamedica.pl/medical_research_journal
Conclusions
I. Morphine decreases bioavailability and antiplatelet 
effect of P2Y12 receptor inhibitors in patients with 
acute MI. 
II. Therapeutic strategies to overcome the interaction 
between morphine and P2Y12 receptor inhibitors 
include: administration of crushed ticagrelor tablets, 
co-administration of metoclopramide, bridging with 
abciximab or cangrelor, or replacement of morphine 
with short-acting alfentanil. 
III. Adequately powered randomised studies exploring 
the influence of concomitant use of morphine and 
P2Y12 receptor inhibitors on clinical outcomes are 
lacking. 
IV. Morphine remains a standard of care in acute MI; 
however, it should be co-administered with anti-
platelet agents after careful evaluation of the clinical 
situation. 
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